The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide

Summary

In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein/low carbohydrate (HP/LC) diet CV parameters, namely arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue, in addition to other metabolic indicators.

Eligibility

Inclusion Criteria:

* Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2
* Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician
* Able to commit for a 6-month trial visits

Exclusion Criteria:

* Pregnant women
* Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months
* Patients who have undergone metabolic weight loss surgery
* Patients known to have diabetes (HbA1c ≥6.5% at screening)
* Patients with uncontrolled hypertension
* Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases
* Patients with excessive alcohol intake, defined as ≥ 2 glasses per day
* Patients known to have uncontrolled/ untreated thyroid disorders.
* Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight
* Patients with untreated gout
* Patients who have undergone bariatric surgery

Conditions2

Browse More Trials